This November

six peptides just got hhs enforcement discretion — cjc-1295 wasn't on the list

On October 28, 2026, HHS issued an interim enforcement discretion policy covering six peptides that licensed 503A compounding pharmacies may now dispense while FDA's formal bulks-list rulemaking continues. The six are BPC-157, TB-500, Epitalon, KPV, MOTS-c, and Semax. [NPR reported the announcement on October 28](https://www.wunc.org/2026-10-28/trump-administration-will-allow-pharmacies-to-make-popular-peptides), and coverage focused on what made the list. What most of that coverage did not note is what didn't. CJC-1295 — the GHRH analog at the center of what is likely the most-prescribed optimization peptide stack in the country — was not covered. That exclusion is not a minor administrative gap. The FDA's Pharmacy Compounding Advisory Committee voted 0 to 13 against recommending CJC-1295 for 503A compounding access in December 2024. Zero committee members in favor. The FDA's own scientific staff, reviewing the evidence before the vote, concluded that CJC-1295 lacked universally accepted chemical characterization — the same finding raised about every peptide on that agenda. What sets CJC-1295 apart from the six that made the HHS list a year later is not explained in the enforcement discretion document. The document names who is covered. CJC-1295 is not on that page, and its absence has not changed what clinics are dispensing this week.

The molecule

cjc-1295 extends the ghrh signal — the dac modification is what makes it different from sermorelin

CJC-1295 is a synthetic analog of growth hormone releasing hormone — the endogenous peptide that instructs the anterior pituitary to release growth hormone in pulses. The DAC modification — Drug Affinity Complex — adds a lysine-based linkage that lets the peptide bind to albumin in the bloodstream, extending the half-life from minutes to several days. That extended residence is the core design feature: it converts a brief pulsatile signal into something closer to continuous GH-axis activation. A second form, CJC-1295 without DAC (also called Modified GRF 1-29), produces a sharper and shorter pulse profile and is more commonly stacked with ipamorelin, a ghrelin receptor agonist that amplifies the pituitary response through a parallel pathway. The standard rationale for combining them is that GHRH and ghrelin-axis signaling are synergistic in GH secretion — the GHRH analog primes the pituitary, and the secretagogue amplifies the response. [PubMed's CJC-1295 literature](https://pubmed.ncbi.nlm.nih.gov/?term=CJC-1295) covers the pharmacokinetic studies that confirmed the extended profile and the early endocrine work. The biology of the modification is not in dispute. What the modification does not change is the evidence picture for the clinical outcomes being marketed.

The pitch

every optimization clinic sells gh pulses, body composition gains, and anti-aging — the gap is the clinical record

The standard optimization pitch for CJC-1295 plus ipamorelin is easy to summarize: combine a GHRH analog with a ghrelin-axis secretagogue, generate more GH pulses, and benefit from improved body composition, faster tissue recovery, better sleep, and slower metabolic aging. The pitch has real internal logic built on real biology — GHRH signaling is established, GH pulsatility matters in physiological context, and the idea of stimulating endogenous production rather than injecting growth hormone directly has a mechanistic rationale. What the pitch conflates is the difference between moving a hormone axis and producing durable clinical outcomes in a healthy adult seeking optimization rather than treating documented GH deficiency. The FDA's December 2024 committee review addressed exactly that gap: it examined the evidence record and voted 0 to 13 against 503A compounding access. The vote did not change the market. Optimization clinic menus running CJC-1295 stacks in November 2026 describe the same story they were selling before the committee met. The October 28 HHS enforcement discretion drew the most recent public regulatory line: six peptides on the covered list, CJC-1295 not among them. The clinics kept going.

What the data says

early pharmacokinetic data moves the axis — the registered trial record does not support the optimization claims

The human evidence for CJC-1295 is real, narrow, and mostly old. A Phase 2 trial published in 2006 enrolled healthy young adults and showed that a single injection produced sustained, dose-dependent increases in serum growth hormone and IGF-1 that lasted four to six days depending on dose. That is a pharmacokinetic result — it confirms the molecule acts on the axis in the intended direction. It does not test body composition outcomes, recovery endpoints, or anti-aging markers in the population or timeframe that drives the 2026 optimization market. [ClinicalTrials.gov's CJC-1295 registry](https://clinicaltrials.gov/search?term=CJC-1295) documents the full registered trial footprint for this molecule. The list is short for the size of the commercial interest. The FDA PCAC briefing materials from December 2024 are the most explicit public summary of what the regulatory scientific review found: the evidence was reviewed, the committee's staff recommended against 503A access, and the advisory vote confirmed the assessment with zero votes in favor. As of November 2026, the data record has not materially changed. [The HHS enforcement discretion policy](https://www.hhs.gov/sites/default/files/hhs-503a-peptide-enforcement-discretion-policy.pdf) naming the six covered peptides makes CJC-1295's exclusion a written regulatory fact, not an inference.

Early human — PeptideFactCheck stance

early endocrine signal is not the same as clinical outcomes for the optimization claims driving this market

CJC-1295 holds PeptideFactCheck's Early human evidence tier. The tier's tone says: interesting enough to watch, too early for broad certainty. The pharmacokinetic literature is what it is — it confirms the molecule extends the GHRH signal, moves the GH axis, and raises measurable IGF-1 levels in enrolled subjects. What the Early human tier does not contain is established clinical outcome evidence for the body composition, recovery, and anti-aging claims appearing in optimization clinic menus and in the stacks being prescribed in November 2026. The 0-to-13 FDA advisory committee vote in December 2024 is the regulatory read on the same gap. The HHS enforcement discretion announcement on October 28 is the operational version of that read: six peptides crossed the threshold for a legal compounding path forward. CJC-1295 did not. Its continued presence in every GH optimization stack menu is not a data-based disagreement with the committee's conclusion — it is a commercial continuation that does not align with where the regulatory picture currently sits. The tier is a receipt. Source trail before certainty.

Editorial boundary

What this page will not do

It will not provide dosing, cycling, sourcing, injection, or personal medical instructions. The job is to classify claims and explain mechanisms.